Heart failure & cardiomyopathiesRandomised controlled trial
Efficacy and Safety of Low-Dose Digoxin in Patients with Heart Failure. Rationale and Design of the DECISION Trial
- Randomised controlled trial (rationale and design)
- double-blind
- parallel-group
- placebo-controlled
- event-driven
- Randomised 1:1
- Endpoints adjudicated blindly by a Clinical Event Committee
- Enrolment completed December 2023
Study context
- Population
- Chronic heart failure (HF) with left ventricular ejection fraction (LVEF) <50%, sinus rhythm or AF, on contemporary HF treatmentenrolment completed
- Participants
- 1,002 participants
- Comparison
- Low-dose digoxin vs placebo
- Primary endpoint
- Composite of cardiovascular (CV) mortality and total HF hospitalizations or total urgent hospital visits for worsening HF
- Follow-up
- Median 3 years
Original publication
Efficacy and Safety of Low-Dose Digoxin in Patients with Heart Failure. Rationale and Design of the DECISION Trial. Eur J Heart Fail. Published 30 August 2024. doi:10.1002/ejhf.3428
Summarised from the published abstract; every number is checked against it